Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation

PLoS Pathogens

Volumn 10, Issue 12, 2014, Pages

  Schuetz, Alexandra ^a,b   Deleage, Claire ^c   Sereti, Irini ^d   Rerknimitr, Rungsun ^e   Phanuphak, Nittaya ^f,g   Phuang Ngern, Yuwadee ^a   Estes, Jacob D ^c   Sandler, Netanya G ^d,j   Sukhumvittaya, Suchada ^a   Marovich, Mary ^h,k   Jongrakthaitae, Surat ^a   Akapirat, Siriwat ^a   Fletscher, James L K ^f   Kroon, Eugene ^a,f   Dewar, Robin ⁱ   Trichavaroj, Rapee ^a   Chomchey, Nitiya ^f,g   Douek, Daniel C ^d   O′Connell, Robert J ^a   Ngauy, Viseth ^a,l   Robb, Merlin L ^b,h   Phanuphak, Praphan ^e,f,g   Michael, Nelson L ^h   Excler, Jean Louis ^b,h   Kim, Jerome H ^f,h   de Souza, Mark S ^a,f,m,n   Ananworanich, Jintanat ^b,f,g,h   more..

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f University Bangkok   (Thailand)

^g THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^h WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^k NATIONAL INSTITUTES OF HEALTH   (United States)

^l TRIPLER ARMY MEDICAL CENTER   (United States)

^m NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

ⁿ NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 22; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CYTOKINE;

ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE RESPONSE; ENDOSCOPIC BIOPSY; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; OPEN STUDY; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; QUANTITATIVE ASSAY; T LYMPHOCYTE ACTIVATION; TH17 CELL; ACUTE DISEASE; BIOPSY; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; HIV INFECTIONS; INTESTINE MUCOSA; MUCOSAL IMMUNITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; SIGMOID; TIME; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTI-RETROVIRAL AGENTS; BIOMARKERS; BIOPSY; COLON, SIGMOID; CYTOKINES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TH17 CELLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84919665923     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004543     Document Type: Article

References (79)

1. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, et al. (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360: 692–698.
2. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, et al. (2011) Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 117: 2791–2799.
3. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, et al. (2012) Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12: 607–614.
4. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, et al. (2013) Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 381: 2109–2117.
5. Grinspoon S, Carr A, (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352: 48–62.
6. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, et al. (2003) Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17: 1871–1879.
7. Cohen MS, Gay CL, Busch MP, Hecht FM, (2010) The detection of acute HIV infection. J Infect Dis 202 Suppl 2: S270–277.
8. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF, (2010) The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10: 11–23.
9. Douek DC, Roederer M, Koup RA, (2009) Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 60: 471–484.
10. Xu H, Wang X, Veazey RS, (2013) Mucosal immunology of HIV infection. Immunol Rev 254: 10–33.
11. Verhoeven D, Sankaran S, Silvey M, Dandekar S, (2008) Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+T cells in gut mucosa but enhances their rapid restoration through central memory T cells. J Virol 82: 4016–4027.
12. Brenchley JM, Douek DC, (2008) HIV infection and the gastrointestinal immune system. Mucosal Immunol 1: 23–30.
13. Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, et al. (2008) Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 14: 421–428.
14. Brenchley JM, Paiardini M, Knox KS, Asher AI, Cervasi B, et al. (2008) Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112: 2826–2835.
15. Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, et al. (2009) Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog 5: e1000295.
16. Ciccone EJ, Greenwald JH, Lee PI, Biancotto A, Read SW, et al. (2011) CD4+T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors. Journal of virology 85: 5880–5888.
17. Bettelli E, Korn T, Oukka M, Kuchroo VK, (2008) Induction and effector functions of T(H)17 cells. Nature 453: 1051–1057.
18. Cecchinato V, Trindade CJ, Laurence A, Heraud JM, Brenchley JM, et al. (2008) Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol 1: 279–288.
19. Huang W, Na L, Fidel PL, Schwarzenberger P, (2004) Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 190: 624–631.
20. Chung DR, Kasper DL, Panzo RJ, Chitnis T, Grusby MJ, et al. (2003) CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol 170: 1958–1963.
21. Chen Y, Thai P, Zhao YH, Ho YS, DeSouza MM, et al. (2003) Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem 278: 17036–17043.
22. Liu JZ, Pezeshki M, Raffatellu M, (2009) Th17 cytokines and host-pathogen interactions at the mucosa: dichotomies of help and harm. Cytokine 48: 156–160.
23. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, et al. (2006) IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 290: G827–838.
24. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, et al. (2008) IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 118: 534–544.
25. Chege D, Sheth PM, Kain T, Kim CJ, Kovacs C, et al. (2011) Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS 25: 741–749.
26. Ciccone EJ, Read SW, Mannon PJ, Yao MD, Hodge JN, et al. (2010) Cycling of gut mucosal CD4+T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels. Mucosal Immunol 3: 172–181.
27. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, et al. (1999) Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 179: 859–870.
28. Mehandru S, Poles MA, Tenner-Racz K, Manuelli V, Jean-Pierre P, et al. (2007) Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol 81: 599–612.
29. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, et al. (2008) Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 3: e2516.
30. Kim CJ, McKinnon LR, Kovacs C, Kandel G, Huibner S, et al. (2013) Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol 191: 2164–2173.
31. Kijak GH, Tovanabutra S, Rerks-Ngarm S, Nitayaphan S, Eamsila C, et al. (2013) Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial. J Virol 87: 7265–7281.
32. Oyomopito RA, Li PC, Sungkanuparph S, Phanuphak P, Tee KK, et al. (2013) Evaluating immunologic response and clinical deterioration in treatment-naive patients initiating first-line therapies infected with HIV-1 CRF01_AE and subtype B. J Acquir Immune Defic Syndr. 62: 293–300.
33. Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, et al. (2012) Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 7: e33948.
34. Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, et al. (2010) HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329: 174–180.
35. Carcelain G, Autran B, (2013) Immune interventions in HIV infection. Immunol Rev 254: 355–371.
36. Waldmann H, Cobbold S, (2009) Regulatory T cells: context matters. Immunity 30: 613–615.
37. Sakaguchi S, Powrie F, (2007) Emerging challenges in regulatory T cell function and biology. Science 317: 627–629.
38. Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, et al. (2011) Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol 85: 11422–11434.
39. Nixon DE, Landay AL, (2010) Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 5: 498–503.
40. Smit-McBride Z, Mattapallil JJ, McChesney M, Ferrick D, Dandekar S, (1998) Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4(+) T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J Virol 72: 6646–6656.
41. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, et al. (2003) Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 77: 11708–11717.
42. Brandtzaeg P, Pabst R, (2004) Let's go mucosal: communication on slippery ground. Trends Immunol 25: 570–577.
43. Veazey RS, Lifson JD, Pandrea I, Purcell J, Piatak M, Jret al. (2003) Simian immunodeficiency virus infection in neonatal macaques. J Virol 77: 8783–8792.
44. Schneider T, Jahn HU, Schmidt W, Riecken EO, Zeitz M, et al. (1995) Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group. Gut 37: 524–529.
45. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. (2004) CD4+T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200: 749–759.
46. Gordon SN, Cervasi B, Odorizzi P, Silverman R, Aberra F, et al. (2010) Disruption of intestinal CD4+T cell homeostasis is a key marker of systemic CD4+T cell activation in HIV-infected individuals. J Immunol 185: 5169–5179.
47. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, et al. (2010) Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 202: 1553–1561.
48. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, et al. (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203: 2271–2279.
49. Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, et al. (2010) Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 115: 335–343.
50. Klatt NR, Brenchley JM, (2010) Th17 cell dynamics in HIV infection. Curr Opin HIV AIDS 5: 135–140.
51. Sodora DL, Silvestri G, (2010) HIV, mucosal tissues, and T helper 17 cells: where we come from, where we are, and where we go from here. Curr Opin HIV AIDS 5: 111–113.
52. Kader M, Wang X, Piatak M, Lifson J, Roederer M, et al. (2009) Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol 2: 439–449.
53. Gougeon ML, Lecoeur H, Dulioust A, Enouf MG, Crouvoiser M, et al. (1996) Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 156: 3509–3520.
54. Jekle A, Keppler OT, De Clercq E, Schols D, Weinstein M, et al. (2003) In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J Virol 77: 5846–5854.
55. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, et al. (2014) Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505: 509–514.
56. Sonnenberg GF, Fouser LA, Artis D, (2011) Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 12: 383–390.
57. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, et al. (2004) IL-22 increases the innate immunity of tissues. Immunity 21: 241–254.
58. De Luca A, Zelante T, D'Angelo C, Zagarella S, Fallarino F, et al. (2010) IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol 3: 361–373.
59. Prendergast A, Prado JG, Kang YH, Chen F, Riddell LA, et al. (2010) HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. AIDS 24: 491–502.
60. Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, et al. (2004) CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 200: 331–343.
61. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF, (2004) Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 78: 2454–2459.
62. Nilsson J, Boasso A, Velilla PA, Zhang R, Vaccari M, et al. (2006) HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 108: 3808–3817.
63. Hartigan-O'Connor DJ, Hirao LA, McCune JM, Dandekar S, (2011) Th17 cells and regulatory T cells in elite control over HIV and SIV. Curr Opin HIV AIDS 6: 221–227.
64. Chevalier MF, Weiss L, (2013) The split personality of regulatory T cells in HIV infection. Blood 121: 29–37.
65. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, et al. (2003) Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17: 1881–1888.
66. Bofill M, Mocroft A, Lipman M, Medina E, Borthwick NJ, et al. (1996) Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS 10: 827–834.
67. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, et al. (2003) T cell activation is associated with lower CD4+T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187: 1534–1543.
68. Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, et al. (2011) Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 25: 2123–2131.
69. Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, et al. (2011) Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 203: 1637–1646.
70. Chun TW, Engel D, Berrey MM, Shea T, Corey L, et al. (1998) Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 95: 8869–8873.
71. Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, et al. (2013) Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 208: 1202–1211.
72. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, et al. (2005) Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 191: 1410–1418.
73. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, et al. (2009) Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 48: 350–361.
74. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, et al. (2008) Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 197: 714–720.
75. Marchetti G, Tincati C, Silvestri G, (2013) Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev 26: 2–18.
76. Sandler NG, Wand H, Roque A, Law M, Nason MC, et al. (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203: 780–790.
77. Sandler NG, Douek DC, (2012) Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 10: 655–666.
78. Ananworanich J, Phanuphak N, de Souza M, Paris R, Arroyo M, et al. (2008) Incidence and characterization of acute HIV-1 infection in a high-risk Thai population. J Acquir Immune Defic Syndr 49: 151–155.
79. Brenchley JM, Vinton C, Tabb B, Hao XP, Connick E, et al. (2012) Differential infection patterns of CD4+T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. Blood 120: 4172–4181.